Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

Executive Summary

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

You may also be interested in...



The World Celebrates Pfizer's 90% COVID-19 Vaccine Efficacy Data, With Cautious Caveats

Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.

Pfizer And BioNTech Claim COVID-19 Vaccine Success

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Regeneron Leaders On Getting A Call From Trump And Building A Bioreactor Farm

Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel